BrightGene Bio-Medical Surges 139.97% in STAR Market Debut

November 8, 2019 11:59 am

Beijing (PingWest)- BrightGene Bio-Medical Technology Co., Ltd, a biopharmaceutical company that engage in manufacturing of medicine and special generic APIs, surged 139.97% in its STAR market debut on Friday

At the time of publication, the stock climbed to CNY30.5 per share, up from CNY12.71 per share IPO price, valuing the company at CNY12.5 billion. BrightGene’s major investor including Sequoia Capital, which is also the company’s largest stakeholder, Highlight Capital and bioVenture.